400 Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFRβ

Saved in:

Bibliographic Details
Published in:	European journal of cancer supplements Vol. 8; no. 7; p. 127
Main Authors:	Gordon, M, Sharma, S, Miller, L, Srinivas, N, Sahu, M, Govindarajan, R, Mullangi, R, Velleca, M, Brittelli, D
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 2010
Subjects:	Hematology, Oncology and Palliative Medicine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
ISSN:	1359-6349 1878-1217
DOI:	10.1016/S1359-6349(10)72107-8